Home » Stocks » CLSN

Celsion Corporation (CLSN)

Stock Price: $0.574 USD 0.044 (8.21%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.570 -0.004 (-0.70%) Nov 27, 4:24 PM

Stock Price Chart

Key Info

Market Cap 21.46M
Revenue (ttm) 500,000
Net Income (ttm) -21.57M
Shares Out 37.42M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.574
Previous Close $0.530
Change ($) 0.044
Change (%) 8.21%
Day's Open 0.520
Day's Range 0.520 - 0.588
Day's Volume 1,097,993
52-Week Range 0.431 - 6.500

More Stats

Market Cap 21.46M
Enterprise Value 9.41M
Earnings Date (est) Mar 31, 2021
Ex-Dividend Date n/a
Shares Outstanding 37.42M
Float 35.28M
EPS (basic) -0.72
EPS (diluted) -0.75
FCF / Share -0.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.34M
Short Ratio 1.50
Short % of Float 3.79%
Beta 2.24
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 42.92
PB Ratio 0.77
Revenue 500,000
Operating Income -18.44M
Net Income -21.57M
Free Cash Flow -17.53M
Net Cash 12.05M
Net Cash / Share 0.32
Gross Margin -2,513.06%
Operating Margin -3,688.04%
Profit Margin -4,314.80%
FCF Margin -3,506.06%
ROA -29.61%
ROE -126.47%
ROIC -80.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$3.00*
Low
3.00
Current: $0.574
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.500.500.500.500.500.500.50-2.00-
Revenue Growth0%0%0%0%0%0%----
Gross Profit0.500.500.500.500.500.500.50-2.00-
Operating Income-20.57-21.07-18.47-20.65-20.85-24.72-15.41-22.14-23.02-19.64
Net Income-16.85-11.88-20.40-22.05-22.46-25.49-8.25-26.57-23.22-18.82
Shares Outstanding21.8317.587.631.851.561.320.970.550.330.20
Earnings Per Share-0.77-0.68-2.72-11.89-14.42-19.32-13.30-48.16-70.00-95.76
Operating Cash Flow-20.26-7.04-16.64-18.38-20.83-21.35-9.53-22.14-22.74-13.37
Capital Expenditures-0.35-0.14-0.04-0.06-0.11-0.67-0.06-0.61-0.57-0.01
Free Cash Flow-20.61-7.18-16.68-18.44-20.94-22.03-9.58-22.76-23.32-13.37
Cash & Equivalents14.8627.6124.174.3020.0736.8642.8723.0330.301.53
Total Debt11.349.42-2.566.429.715.015.070.180.18
Net Cash / Debt3.5318.1924.171.7413.6427.1537.8617.9630.121.35
Assets38.2846.8647.5130.8549.0366.6945.6725.3632.652.53
Liabilities23.7225.9920.8124.1228.6433.8714.1513.406.467.10
Book Value14.5620.8626.706.7320.3932.8331.5211.9626.19-4.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Celsion Corporation
Country United States
Employees 29
CEO Michael H. Tardugno

Stock Information

Ticker Symbol CLSN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLSN
IPO Date March 5, 1985

Description

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.